{"id":"9794f8c0-1cc1-53ad-b4d2-1277ea07760d","stable_key":"584c58f5-ab9f-53f3-97a9-55783db943b0:tryptophan-nam-clinical","predicate":"increases","statement":"A phase-1 placebo-controlled oral nicotinamide study showed dose-related increases in circulating NAD metabolites and an exploratory association with less acute kidney injury.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"c52dffd9-4447-5adb-ac31-aa77fc6758cf","mechanism_event_label":"An alternate NAD precursor reached downstream metabolism in a human pilot.","subject":{"id":"08c27a3f-552e-5c92-8688-321a9b64a0d6","slug":"nicotinamide","display_name":"Nicotinamide","entity_type_key":"small_molecule"},"object":{"id":"c2402222-bfa4-5cdc-a523-63010340f252","slug":"human-nam-nad-metabolites","display_name":"Human circulating NAD metabolites after nicotinamide","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c52dffd9-4447-5adb-ac31-aa77fc6758cf","stable_key":"584c58f5-ab9f-53f3-97a9-55783db943b0:tryptophan-nam-clinical-event","event_type":"observed_relationship","label":"An alternate NAD precursor reached downstream metabolism in a human pilot.","description":"A phase-1 placebo-controlled oral nicotinamide study showed dose-related increases in circulating NAD metabolites and an exploratory association with less acute kidney injury.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"08c27a3f-552e-5c92-8688-321a9b64a0d6","slug":"nicotinamide","display_name":"Nicotinamide","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"c2402222-bfa4-5cdc-a523-63010340f252","slug":"human-nam-nad-metabolites","display_name":"Human circulating NAD metabolites after nicotinamide","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"769339cb-213b-559e-acc0-07ed00368b94","slug":"l-tryptophan","display_name":"L-Tryptophan","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human phase-1 study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not a definitive kidney-protection trial or proof that every blocked de novo step can be clinically bypassed.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Tryptophan collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"l-tryptophan","display_name":"L-Tryptophan","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"An alternate NAD precursor reached downstream metabolism in a human pilot.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"De novo NAD+ biosynthetic impairment in acute kidney injury in humans. · 2018 · https://pubmed.ncbi.nlm.nih.gov/30127395/ · DOI 10.1038/s41591-018-0138-z","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"0903b06b-044f-5f2c-ab46-7909de6df16d","evidence_kind":"source_excerpt","locator":"Lines 266-272","start_line":266,"end_line":272,"excerpt":"## tryptophan-nam-clinical\nAn alternate NAD precursor reached downstream metabolism in a human pilot.\nA phase-1 placebo-controlled oral nicotinamide study showed dose-related increases in circulating NAD metabolites and an exploratory association with less acute kidney injury.\nModel: Human phase-1 study.\nLimitations: Not a definitive kidney-protection trial or proof that every blocked de novo step can be clinically bypassed.\nEvidence access: Primary abstract\nDe novo NAD+ biosynthetic impairment in acute kidney injury in humans. · 2018 · https://pubmed.ncbi.nlm.nih.gov/30127395/ · DOI 10.1038/s41591-018-0138-z","model_system":"Human phase-1 study.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"73f9d3e7-fdc9-5418-8f3c-f4ef145f6efa","stable_key":"import-584c58f5-ab9f-53f3-97a9-55783db943b0","title":"Tryptophan: transport, protein synthesis, neuroactive metabolites, NAD and microbial pathways (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"7dfd20063b91900cb5c6ad675e3e675b7e25ef0fb8304eabac6f263cc5518284","revision_id":"bfafd789-fdf5-521f-bd28-c662e01ec1ea","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}